208 related articles for article (PubMed ID: 22841019)
1. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients.
Briere TM; Crane CH; Beddar S; Bhosale P; Mok H; Delclos ME; Krishnan S; Das P
Radiother Oncol; 2012 Aug; 104(2):161-6. PubMed ID: 22841019
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric Predictors of Radiation-Induced Vaginal Stenosis After Pelvic Radiation Therapy for Rectal and Anal Cancer.
Son CH; Law E; Oh JH; Apte AP; Yang TJ; Riedel E; Wu AJ; Deasy JO; Goodman KA
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):548-54. PubMed ID: 25936810
[TBL] [Abstract][Full Text] [Related]
4. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
5. Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) - a prospective, randomized, 2-armed phase-II-trial.
Arians N; Häfner M; Krisam J; Lang K; Wark A; Koerber SA; Hommertgen A; Debus J
BMC Cancer; 2020 Jan; 20(1):52. PubMed ID: 31964381
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
7. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
Elson JK; Kachnic LA; Kharofa JR
Cancer; 2018 Nov; 124(22):4383-4392. PubMed ID: 30329160
[TBL] [Abstract][Full Text] [Related]
9. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
10. Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT.
Dell'Acqua V; Kobiela J; Kraja F; Leonardi MC; Surgo A; Zerella MA; Arculeo S; Fodor C; Ricotti R; Zampino MG; Ravenda S; Spinoglio G; Biffi R; Bazani A; Luraschi R; Vigorito S; Spychalski P; Orecchia R; Glynne-Jones R; Jereczek-Fossa BA
Med Oncol; 2018 Mar; 35(5):59. PubMed ID: 29594584
[TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
12. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.
Ghareeb A; Paramasevon K; Mokool P; van der Voet H; Jha M
Ann R Coll Surg Engl; 2019 Mar; 101(3):168-175. PubMed ID: 30482037
[TBL] [Abstract][Full Text] [Related]
14. Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy.
Ho KF; Marchant T; Moore C; Webster G; Rowbottom C; Penington H; Lee L; Yap B; Sykes A; Slevin N
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e375-82. PubMed ID: 22197229
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
18. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
20. Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer.
Koeck J; Lohr F; Buergy D; Büsing K; Trunk MJ; Wenz F; Mai S
Radiat Oncol; 2016 Apr; 11():53. PubMed ID: 27044498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
